Search hospitals > Maine > Portland
Maine Medical Center
Claim this profilePortland, Maine 04102
Global Leader in Parotid Gland Cancer
Global Leader in Cervical Adenocarcinoma
Conducts research for Coronary Artery Disease
Conducts research for Ovarian Cancer
Conducts research for Relapse
319 reported clinical trials
21 medical researchers
Summary
Maine Medical Center is a medical facility located in Portland, Maine. This center is recognized for care of Parotid Gland Cancer, Cervical Adenocarcinoma, Coronary Artery Disease, Ovarian Cancer, Relapse and other specialties. Maine Medical Center is involved with conducting 319 clinical trials across 458 conditions. There are 21 research doctors associated with this hospital, such as Eric C. Larsen, Matthew D. Cheney, Leslie Bradford, MD, and Christine Lu-Emerson.Area of expertise
1Parotid Gland Cancer
Global LeaderStage I
Stage II
Stage IV
2Cervical Adenocarcinoma
Global LeaderStage II
Stage IV
Stage III
Top PIs
Eric C. LarsenMaine Children's Cancer Program8 years of reported clinical research
Studies Lymphoma
Studies Adult T-Cell Leukemia/Lymphoma
24 reported clinical trials
67 drugs studied
Matthew D. CheneyMaine Medical Center- Scarborough Campus5 years of reported clinical research
Studies Parotid Gland Cancer
Studies Breast Cancer
22 reported clinical trials
60 drugs studied
Leslie Bradford, MDMaine Medical Center- Scarborough Campus2 years of reported clinical research
Expert in Ovarian Cancer
Studies Parotid Gland Cancer
22 reported clinical trials
52 drugs studied
Christine Lu-EmersonMaine Medical Center- Scarborough Campus3 years of reported clinical research
Studies Glioblastoma
Studies Brain Tumor
8 reported clinical trials
18 drugs studied
Clinical Trials running at Maine Medical Center
Prostate Cancer
Testicular cancer
Kidney Cancer
Parotid Gland Cancer
Cancer
Small Cell Lung Cancer
Esophageal Adenocarcinoma
Acute Myeloid Leukemia
Prostate Adenocarcinoma
Prostatic Neoplasm
Shorter vs Usual Radiation Therapy
for Prostate Cancer
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.
Recruiting2 awards Phase 310 criteria
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting2 awards Phase 3
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Maine Medical Center?
Where is Maine Medical Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does Maine Medical Center accept?
What awards or recognition has Maine Medical Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.